Gene Panel Market Size, Revenue, Forecast Report 2026 to 2035

What is Gene Panel Market Size?

Gene Panel Market Size is valued at USD 49.96 Bn in 2025 and is predicted to reach USD 335.96 Bn by the year 2035 at a 21.2% CAGR during the forecast period for 2026 to 2035.

Gene Panel Market Size, Share & Trends Analysis Distribution by Technique (Amplicon-Based, Hybridization-Based), by Design (Predesigned Gene Panels, Customised Gene Panels), by Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), by End User (Research and Academic Institutes, Hospital and Diagnostic Laboratories, Biotechnology and Pharmaceutical Companies) and Segment Forecasts, 2026 to 2035

The Gene Panel Market focuses on genetic tests that examine specific groups of genes linked to certain diseases or conditions. These tests help find genetic mutations, support early detection, guide treatment choices, and improve patient care through precision medicine. Gene panels are used in areas like cancer, rare disease diagnosis, inherited disorder screening, reproductive health, pharmacogenetics, and clinical research. They often use advanced technologies such as next-generation sequencing (NGS), amplicon-based sequencing, and hybridization-based methods, allowing for accurate and efficient analysis of many genes at once. The market serves hospitals, diagnostic labs, research institutes, biotech companies, and pharmaceutical organizations that use genomic information to improve diagnosis, drug development, and personalized healthcare. 

The market is growing as precision medicine becomes more important in healthcare. With more cases of cancer, inherited disorders, and other genetic diseases, there is a greater need for quick and reliable genetic testing. More healthcare providers are choosing gene panel tests because they give thorough results and save time and money compared to testing one gene at a time. Greater awareness of personalized medicine, more uses for genomic research, and higher investments in molecular diagnostics are also helping the market grow. Pharmaceutical and biotech companies are using gene panels to find biomarkers, support clinical trials, and develop targeted treatments, which is opening up new opportunities in healthcare.

Ongoing advances in technology are making gene panel testing quicker, more accurate, and easier to access. Better next-generation sequencing platforms, improved bioinformatics software, new data analysis tools, and more automation help labs process more samples efficiently. Companies are also creating custom and disease-specific gene panels to meet the rising demand for precise diagnostics in fields like cancer, heart disease, neurology, reproductive medicine, and rare diseases. Partnerships among diagnostic companies, research groups, healthcare providers, and pharmaceutical firms are speeding up innovation and helping gene panel testing become more widely used around the world. Even though the market has strong growth potential, it faces some challenges. 

Advanced genomic technologies are expensive, and in some countries, there is limited reimbursement. Specialized lab infrastructure is also needed, which can make adoption harder. Interpreting complex genetic data requires skilled staff and strong bioinformatics tools, and rules for clinical validation and data privacy are still changing. Differences in healthcare systems and access to genetic testing in different regions may also slow market growth in developing countries.

Looking forward, the future of the gene panel market looks very positive. More people are using precision medicine, there is higher demand for early disease detection, companion diagnostics are being used in more ways, and investment in genomics research is growing. As sequencing technologies get cheaper and healthcare focuses more on personalized treatment, gene panel testing will likely become a regular part of clinical practice. Ongoing advances in molecular diagnostics, AI-assisted genomic analysis, and targeted therapies will make gene panels even more important for improving patient outcomes and shaping the future of precision healthcare.

Competitive Landscape

Which are the Leading Players in the Gene Panel Market?

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Danaher Corporation 
• Twist Bioscience Corporation
• Labcorp Holdings Inc. 
• Myriad Genetics, Inc.
• Roche Holding Ltd.
• Fulgent Genetics, Inc.
• GeneDx Holdings Corp.
• Personalis, Inc.
• BGI Genomics Co., Ltd.
• Novogene Co., Ltd.
• Azenta, Inc. 
• Eurofins Scientific SE

Market Dynamics

Driver

Growing Adoption of Precision Medicine and Increasing Demand for Genetic Testing

The gene panel market is growing steadily as more healthcare providers use precision medicine to offer personalized and effective treatments. With more cases of cancer, inherited disorders, rare diseases, and other genetic conditions, there is a greater need for accurate genetic testing. Gene panels let clinicians analyze several disease-related genes at once, which helps them diagnose conditions faster, find disease-causing mutations, and choose targeted treatments. Ongoing improvements in next-generation sequencing, more awareness of genetic screening, and new uses in oncology, reproductive health, and pharmacogenetics are also boosting the market. More investment in genomics research and personalized healthcare is helping gene panel testing become more common in both clinical and research settings.

Restrain/Challenge

High Testing Costs and Complex Data Interpretation

Even though the Gene Panel Market has strong growth potential, it faces some challenges. Advanced gene panel testing needs high-tech sequencing equipment, specialized labs, and skilled staff, which makes testing expensive in many places. Interpreting complex genetic data also requires advanced bioinformatics tools and experienced specialists to ensure clinical decisions are accurate. Rules, privacy concerns, and the need for thorough clinical validation can raise costs and slow down the launch of new tests. Limited insurance coverage and unequal access to genomic testing in developing countries can also slow the use of gene panel technologies.

Predesigned Gene Panels Segment is Expected to Drive the Gene Panel Market

The Predesigned Gene Panels segment is expected to make up a large part of the Gene Panel Market in the coming years. These panels are popular because they offer standardized and clinically proven tests for diseases like cancer, inherited disorders, and heart conditions. Healthcare providers like predesigned panels because they are faster, reliable, and make lab work easier. As more people need routine genetic testing, predesigned gene panels will likely keep being used widely in hospitals, diagnostic labs, and research centers.

Cancer Risk Assessment Segment is Expected to Drive the Gene Panel Market

The Cancer Risk Assessment segment is anticipated to hold a leading position in the market due to the increasing global burden of cancer and the growing use of genomic testing in oncology. Gene panel testing helps identify inherited cancer-related mutations, supports early diagnosis, guides targeted therapy selection, and assists clinicians in making personalized treatment decisions. The increasing use of precision oncology, companion diagnostics, and biomarker-based therapies is expected to further strengthen demand for gene panel testing in cancer risk assessment throughout the forecast period.

Why North America Leads the Gene Panel Market?

North America continues to lead the Gene Panel Market due to its well-established healthcare infrastructure, advanced genomic research capabilities, and widespread adoption of precision medicine. The United States is home to leading biotechnology companies, diagnostic laboratories, pharmaceutical manufacturers, and research institutions that actively develop and commercialise advanced genetic testing technologies. Strong government and private-sector investments in genomics research, increasing adoption of next-generation sequencing, and growing demand for personalized healthcare continue to support market expansion across the region.

Key Developments-

• In July 2026, Labcorp launched the Marker by Labcorp Genetic Health Panel, which analyzes 163 genes associated with more than 100 medically actionable hereditary conditions, including cancer, cardiovascular and metabolic disorders.

Gene Panel Market Report Scope: